IFN-γ licenses CD11b+ cells to induce progression of systemic lupus erythematosus

Journal of Autoimmunity

Volumn 62, Issue , 2015, Pages 11-21

  Shaabani, Namir ^a,b   Honke, Nadine ^a,b   Dolff, Sebastian ^a   Görg, Boris ^b   Khairnar, Vishal ^a   Merches, Katja ^a   Duhan, Vikas ^a   Metzger, Sabine ^c   Recher, Mike ^d   Barthuber, Carmen ^b   Hardt, Cornelia ^a   Proksch, Peter ^b   Häussinger, Dieter ^b   Witzke, Oliver ^a   Lang, Philipp A ^b   Lang, Karl S ^a,b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Autoantibodies; Fcgr2b; IFN ; Infection; Inflammation; Systemic lupus erythematosus; Virus

Indexed keywords

AUTOANTIBODY; CD11B ANTIGEN; FC RECEPTOR; GAMMA INTERFERON;

ADAPTIVE IMMUNITY; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BONE MARROW; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; FEMALE; GENETIC VARIABILITY; GLOMERULUS; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LIVER CELL DAMAGE; MALE; MOUSE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; SEX DIFFERENCE; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TISSUE INJURY; UPREGULATION; ANIMAL; DISEASE MODEL; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; METABOLISM; RECURRENT DISEASE;

ANIMALS; ANTIGENS, CD11B; AUTOANTIBODIES; AUTOIMMUNITY; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; INTERFERON-GAMMA; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MICE; MICE, KNOCKOUT; RECEPTORS, IGG; RECURRENCE;

EID: 84939571189     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.05.007     Document Type: Article

References (59)

1. Wiik A. Autoantibodies in vasculitis. Arthritis Res. Ther. 2003, 5:147-152.
2. Baslund B., Wiik A. Anti-neutrophil cytoplasmic autoantibodies (ANCA) and vasculitis. Clin. Rev. Allergy 1994, 12:297-304.
3. Lipsky P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. 2001, 2:764-766.
4. Eggert M., Zettl U.K., Neeck G. Autoantibodies in autoimmune diseases. Curr. Pharm. Des. 2010, 16:1634-1643.
5. Bogdanos D.P., Mieli-Vergani G., Vergani D. Autoantibodies and their antigens in autoimmune hepatitis. Semin. Liver Dis. 2009, 29:241-253.
6. Lee S.J., Kavanaugh A. 4. Autoimmunity, vasculitis, and autoantibodies. J.Allergy Clin. Immunol. 2006, 117:S445-S450.
7. Tsokos G.C. Systemic lupus erythematosus. N.Engl. J. Med. 2011, 365:2110-2121.
8. Preble O.T., Black R.J., Friedman R.M., Klippel J.H., Vilcek J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982, 216:429-431.
9. Nagata S., Hanayama R., Kawane K. Autoimmunity and the clearance of dead cells. Cell 2010, 140:619-630.
10. Rumore P.M., Steinman C.R. Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone. J.Clin. Invest. 1990, 86:69-74.
11. McGaha T.L., Sorrentino B., Ravetch J.V. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Sci. (New York, N. Y. ) 2005, 307:590-593.
12. Paunovic V., Carter N.A., Thalhamer T., Blair D., Gordon B., Lacey E., Michie A.M., Harnett M.M. Immune complex-mediated co-ligation of the BCR with FcgammaRIIB results in homeostatic apoptosis of B cells involving Fas signalling that is defective in the MRL/Lpr model of systemic lupus erythematosus. J.Autoimmun. 2012, 39:332-346.
13. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8:34-47.
14. Kyogoku C., Dijstelbloem H.M., Tsuchiya N., Hatta Y., Kato H., Yamaguchi A., Fukazawa T., Jansen M.D., Hashimoto H., van de Winkel J.G., et al. Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum. 2002, 46:1242-1254.
15. Arbuckle M.R., McClain M.T., Rubertone M.V., Scofield R.H., Dennis G.J., James J.A., Harley J.B. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N.Engl. J. Med. 2003, 349:1526-1533.
16. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J.Exp. Med. 2003, 197:711-723.
17. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 2006, 6:823-835.
18. Gota C., Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 2003, 36:511-518.
19. Santiago-Raber M.L., Baccala R., Haraldsson K.M., Choubey D., Stewart T.A., Kono D.H., Theofilopoulos A.N. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J.Exp. Med. 2003, 197:777-788.
20. Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006, 25:417-428.
21. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J.Leukoc. Biol. 2004, 75:163-189.
22. Hervas-Stubbs S., Perez-Gracia J.L., Rouzaut A., Sanmamed M.F., Le Bon A., Melero I. Direct effects of type I interferons on cells of the immune system. Clin. Cancer Res. 2011, 17:2619-2627.
23. Boehm U., Klamp T., Groot M., Howard J.C. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 1997, 15:749-795.
24. Zhang X., Sun S., Hwang I., Tough D.F., Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells invivo by IL-15. Immunity 1998, 8:591-599.
25. Montoya M., Schiavoni G., Mattei F., Gresser I., Belardelli F., Borrow P., Tough D.F. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 2002, 99:3263-3271.
26. Rahman A., Isenberg D.A. Systemic lupus erythematosus. N.Engl. J. Med. 2008, 358:929-939.
27. Willcocks L.C., Carr E.J., Niederer H.A., Rayner T.F., Williams T.N., Yang W., Scott J.A., Urban B.C., Peshu N., Vyse T.J., et al. Adefunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus. Proc. Natl. Acad. Sci. U S A 2010, 107:7881-7885.
28. Fukuyama H., Nimmerjahn F., Ravetch J.V. The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat. Immunol. 2005, 6:99-106.
29. Leiss H., Niederreiter B., Bandur T., Schwarzecker B., Bluml S., Steiner G., Ulrich W., Smolen J.S., Stummvoll G.H. Pristane-induced lupus as a model of human lupus arthritis: evolvement of autoantibodies, internal organ and joint inflammation. Lupus 2013, 22:778-792.
30. Lang P.A., Recher M., Haussinger D., Lang K.S. Genes determining the course of virus persistence in the liver: lessons from murine infection with lymphocytic choriomeningitis virus. Cell. Physiol. Biochem. 2010, 26:263-272.
31. Kagi D., Ledermann B., Burki K., Zinkernagel R.M., Hengartner H. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis invivo. Annu. Rev. Immunol. 1996, 14:207-232.
32. Zinkernagel R.M. Lymphocytic choriomeningitis virus and immunology. Curr. Top. Microbiol. Immunol. 2002, 263:1-5.
33. Thale C., Kiderlen A.F. Sources of interferon-gamma (IFN-gamma) in early immune response to Listeria monocytogenes. Immunobiology 2005, 210:673-683.
34. Lang P.A., Contaldo C., Georgiev P., El-Badry A.M., Recher M., Kurrer M., Cervantes-Barragan L., Ludewig B., Calzascia T., Bolinger B., et al. Aggravation of viral hepatitis by platelet-derived serotonin. Nat. Med. 2008, 14:756-761.
35. Recher M., Lang K.S., Navarini A., Hunziker L., Lang P.A., Fink K., Freigang S., Georgiev P., Hangartner L., Zellweger R., et al. Extralymphatic virus sanctuaries as a consequence of potent T-cell activation. Nat. Med. 2007, 13:1316-1323.
36. Radeke H.H., Janssen-Graalfs I., Sowa E.N., Chouchakova N., Skokowa J., Loscher F., Schmidt R.E., Heeringa P., Gessner J.E. Opposite regulation of type II and III receptors for immunoglobulin G in mouse glomerular mesangial cells and in the induction of anti-glomerular basement membrane (GBM) nephritis. J.Biol. Chem. 2002, 277:27535-27544.
37. Joller N., Weber S.S., Muller A.J., Sporri R., Selchow P., Sander P., Hilbi H., Oxenius A. Antibodies protect against intracellular bacteria by Fc receptor-mediated lysosomal targeting. Proc. Natl. Acad. Sci. U S A 2010, 107:20441-20446.
38. Toussirot E., Roudier J. Epstein-Barr virus in autoimmune diseases. Best. Pract. Res. Clin. Rheumatol. 2008, 22:883-896.
39. Harley J.B., James J.A. Epstein-Barr virus infection induces lupus autoimmunity. Bull. NYU Hosp. Jt. Dis. 2006, 64:45-50.
40. Ramos-Casals M., Pares A., Jara L.J., Solans R., Vinas O., Vazquez P., Sanchez-Tapias J.M., Rodes J., Font J. Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature. J.Viral Hepat. 2005, 12:648-654.
41. Ijichi S., Osame M. Human T-cell lymphotropic virus type I and systemic lupus erythematosus. Intern. Med. 1999, 38:459-460.
42. Morgan E.M., Rapp F. Measles virus and its associated diseases. Bacteriol. Rev. 1977, 41:636-666.
43. Gyorkey F., Min K.W., Sincovics J.G., Gyorkey P. Systemic lupus erythematosus and myxovirus. N.Engl. J. Med. 1969, 280:333.
44. Ziff M. Viruses and the connective tissue diseases. Ann. Intern. Med. 1971, 75:951-958.
45. Christian C.L., Phillips P.E. Viruses and autoimmunity. Am. J. Med. 1973, 54:611-620.
46. Perl A., Fernandez D., Telarico T., Phillips P.E. Endogenous retroviral pathogenesis in lupus. Curr. Opin. Rheumatol. 2010, 22:483-492.
47. Agmon-Levin N., Blank M., Paz Z., Shoenfeld Y. Molecular mimicry in systemic lupus erythematosus. Lupus 2009, 18:1181-1185.
48. Kaplan M.J. Neutrophils in the pathogenesis and manifestations of SLE. Nat. Rev. Rheumatol. 2011, 7:691-699.
49. Villanueva E., Yalavarthi S., Berthier C.C., Hodgin J.B., Khandpur R., Lin A.M., Rubin C.J., Zhao W., Olsen S.H., Klinker M., et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J.Immunol. 2011, 187:538-552.
50. Carmona-Rivera C., Kaplan M.J. Low-density granulocytes: a distinct class of neutrophils in systemic autoimmunity. Semin. Immunopathol. 2013, 35:455-463.
51. Ren Y., Tang J., Mok M.Y., Chan A.W., Wu A., Lau C.S. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum. 2003, 48:2888-2897.
52. Lieberman L.A., Tsokos G.C. The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity. J.Biomed. Biotechnol. 2010, 740619.
53. Wigfall D.R., Sakai R.S., Wallace D.J., Jordan S.C. Interleukin-2 receptor expression in peripheral blood lymphocytes from systemic lupus erythematosus patients: relationship to clinical activity. Clin. Immunol. Immunopathol. 1988, 47:354-362.
54. Blanco P., Pitard V., Viallard J.F., Taupin J.L., Pellegrin J.L., Moreau J.F. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2005, 52:201-211.
55. Dolff S., Abdulahad W.H., Arends S., van Dijk M.C., Limburg P.C., Kallenberg C.G., Bijl M. Urinary CD8+ T-cell counts discriminate between active and inactive lupus nephritis. Arthritis Res. Ther. 2013, 15:R36.
56. Dolff S., Abdulahad W.H., van Dijk M.C., Limburg P.C., Kallenberg C.G., Bijl M. Urinary T cells in active lupus nephritis show an effector memory phenotype. Ann. Rheum. Dis. 2010, 69:2034-2041.
57. Recher M., Lang K.S., Hunziker L., Freigang S., Eschli B., Harris N.L., Navarini A., Senn B.M., Fink K., Lotscher M., et al. Deliberate removal of T cell help improves virus-neutralizing antibody production. Nat. Immunol. 2004, 5:934-942.
58. Lang K.S., Georgiev P., Recher M., Navarini A.A., Bergthaler A., Heikenwalder M., Harris N.L., Junt T., Odermatt B., Clavien P.-A., et al. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J.Clin. Invest. 2006, 116:2456-2463.
59. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40:1725.